# Janssen Research & Development, LLC: Phase 3 study closed enrollment, 864 enrolled (Multiple Myeloma)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment |
| NCT ID | NCT05455320 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Multiple Myeloma |
| Intervention types | drug |
| Target enrollment | 864 |
| Site countries | United States, Belgium, Brazil, China, Czechia, France, Germany, Greece, Israel, Italy, Japan, Netherlands |
| Posted | 2022-07-13 |
| Planned start | 2022-10-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 864 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05455320). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.